The Prostate Cancer Therapeutics Market Forecast 2014-2024

LONDON, July 21, 2014 /PRNewswire/ --

Opportunities for Leading Companies 

Where is the prostate cancer therapeutics market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects.

Our 208-page report provides 160 tables, charts, and graphs. Our new study lets you assess leading drugs and devices in the prostate cancer therapeutics market, showing their prospects to 2024. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects 

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

- Professor Malcolm Mason, Cancer Research UK
- Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
- Dr. Estuardo Aguilar-Cordova, Co-Founder, CEO and Chairman, Advantagene

Discover sales predictions for the world market and submarkets 

Along with revenue predictions for the overall world market, you can see revenue forecasts to 2024 for the main submarkets:

- Prostate cancer drugs
- Prostate cancer devices

Our investigation discusses what stimulates and restrains business. You will find dynamics of the industry and be able to assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for prostate cancer drugs and devices 

How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 9 leading prostate cancer drugs, including:

- Zytiga sales forecast 2014-2024
- Lupron sales forecast 2014-2024
- Xtandi sales forecast 2014-2024
- Zoladex sales forecast 2014-2024
- Casodex sales forecast 2014-2024
- Jevtana sales forecast 2014-2024
- Provenge sales forecast 2014-2024
- Taxotere sales forecast 2014-2024
- Xofigo sales forecast 2014-2024

Our new study also discusses promising drugs in the late stages of development 

How will the prostate cancer devices market perform to 2024? Our study forecasts sales for the main device submarkets, including these:

- The brachytherapy market forecast 2014-2024
- The radical prostatectomy market forecast 2014-2024
- The external beam radiation market forecast 2014-2024
- The cryotherapy market forecast 2014-2024
- The HIFU market forecast 2014-2024

Discover how high revenues can go. You can see what's happening, and understand trends, challenges and opportunities.

Our analysis also breaks the main world market into geographical markets.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

What are the prospects in the leading regions and countries? 

In addition to analyses of the overall world market, you will discover individual revenue forecasts for 13 national markets to 2024:

- US
- Japan
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Brazil
- Russia
- India
- China
- South Korea
- Mexico
- Rest of the World

There will be growth in established pharmaceutical and medical devices markets and in developing countries. Our analyses show that India, Brazil, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth 

Overall world revenue for prostate cancer therapeutics will reach $7bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for prostate cancer drugs and procedures, expanding healthcare coverage and the success of novel diagnostics will increase sales to 2024.

Our work shows you which organisations hold greatest potential. See profiles of 7 leading companies:

- Johnson and Johnson
- AstraZeneca
- Sanofi
- AbbVie
- Varian Medical Systems
- Elekta
- Theragenics Corporation (Juniper)

A company profile gives you the following information:

- Discussion of a company's activities and outlook
- Recent financial results
- Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the prostate cancer therapeutics market?
Our new report discusses issues and events affecting the prostate cancer therapeutics market. You will find discussions, including qualitative analyses:

- Drugs targeting mCRPC - driving market growth
- Strong pipeline of drugs in development
- Robotic prostatectomy - showing strong growth
- Prostate cancer market driven by an aging population
- International expansion - targeting emerging national markets
- Stem cells - offering opportunities for growth
- High rivalry among competitors

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

How The Prostate Cancer Therapeutics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 208-page report gives you the following knowledge:

- Revenues forecast to 2024 for the world prostate cancer therapeutics market and its submarkets - discover the industry's prospects, finding promising places for investments and revenues
- Revenue forecasts to 2024 for the leading 13 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, Rest of Europe, India, Brazil, Russia, Mexico, South Korea and Rest of the World
- Assessment of 7 leading companies - hear about products, results and strategies
- Predicted revenues of 9 leading drugs and 5 medical procedures to 2024 - see the potentials of top products
- Review of R&D pipelines - investigate developmental trends and progress
- Discussion of what stimulates and restrains companies and the market
- Prospects for established firms and those seeking to enter the market
- View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else 

With our survey you are less likely to fall behind in knowledge or miss an opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the prostate cancer therapeutics market and leading companies. You find data, trends and predictions. Please order our report now.

Companies Listed in this Report 

AbbVie
Accord Healthcare
Actavis
Active Biotech
Advanced Medical Isotope Corporation
Advantagene
Agensys
Algeta
Aragon Pharmaceuticals (J&J)
Astellas
AstraZeneca
Bavarian Nordic
Bayer
Beckman Coulter (Danaher)
Bellicum Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
Computer Motion
Cougar Biotechnology
CP Medical
CR Bard
Dendreon
Elekta
EMD Serono
Exelixis
Firmagon
Galt Medical
GenomeDx Biosciences
Genomic Health
Gen-Probe (Hologic)
Hologic
Intuitive Surgical
Ipsen
Iris International (Danaher)
Janssen (J&J)
Johnson & Johnson
Juniper
Macrogenics
MDxHealth
Medivation
Merck
Merial (Sanofi)
Metabolon
Metamark Genetics
Millenium Pharmaceuticals
Mitomics
Mylan Pharmaceuticals
Myriad Genetics
Needle Tech Products
NorthWest Biotherapeutics
Nucletron
OncoGenex
Oncura
Opko Health
Philips
Progenics
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens
Steba Biotech
Sun Pharmaceuticals
Sython Pharmaceuticals
Teva
Theragenics
Tokai
Varian Medical Systems
Xgeva
Zydus

Other Organisations Mentioned in this Report
Cedars-Sinai Medical Center
European Association of Urology
Levine Cancer Institute
Medical Research council (MRC)
Ministry of Health, Labour, and Welfare (MHLW) (Japanese)
National Cancer Institute
National Health Service (UK)
Prostate Cancer UK
The American Cancer Society
The American Society of Clinical Oncology (ASCO)
The Food and Drug Administration (FDA) (US)
The Froedtert & Medical College of Wisconsin Clinical Cancer Centre
The Italian National Health Service (INHS)
The National Institute of Clinical Excellence (NICE)
The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital (Netherlands)
The Sunnybrook Health Sciences (Ontario)
The University Medical Centre Utrecht (Netherlands)
The University of Adelaide
The University of California
The University of Cardiff
The University of Texas MD Anderson Centre (Texas)
The University of York
U.S. Center for Medicare and Medicaid Services (CMS)
UK National Cancer Research Network Prostate Cancer Clinical Studies Group
US Department of Defense
US Preventative Services Task Force (USPSTF)
World Cancer Research Fund International
World Health Organisation (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44-(0)-20-7336-6100 or click on https://www.visiongain.com/Report/1294/The-Prostate-Cancer-Therapeutics-Market-Forecast-2014-2024